Quantitative levels of anti-Pneumocystis jirovecii major surface glycoprotein IgG and IgM antibodies in HIV and non-HIV groups

Abstract

Abstract:

Objective To investigate the quantitative levels of anti-Pneumocystis jirovecii (Pj) major surface glycoprotein (Msg) IgG and IgM antibodies in HIV and non-HIV groups to explore its value in epidemiological investigation.Method One target sequence of Pj Msg gene was selected and expressed using prokaryotic expression system.Enzyme-linked immunosorbent assay (ELISA) was established to detect anti-Pj Msg IgG and IgM antibodies using recombinant Pj Msg as antigen.Multiple proportion dilution methods were established to measure quantitative levels of anti-Pj Msg IgG and IgM antibodies.A cohort of individuals with HIV infection (n=176) and non HIV controls (n=266) in Beijing China were investigated.All patients were not diagnosed with a situation of pneumocystis pneumonia (PCP).Results The positive rate of anti-Pj Msg IgG antibody in non-HIV group was 42.5% (113/266).Among these 113 positive cases,there were 77 cases (68.1%),15 cases (13.3%),6 cases (5.3%),and 15 cases (13.3%) in the titer of 1:100,1:200,1:400,and 1:800 levels respectively.The positive rate of anti-Pj Msg IgG antibody in HIV infection group was 24.4% (43/176).Among these 43 positive cases,there were 28 cases (65.1%),10 cases (23.3%),3 cases (7.0%),and 2 cases (4.7%) in the titer of 1:100,1:200,1:400,and 1:800 levels respectively.There was no statistical significance in the difference of anti-Pj Msg IgG antibody titer levels compared with non-HIV controls (χ²=4.254,P=0.235).The positive rate of anti-Pj Msg IgM antibody in non-HIV group was 41.7% (111/266).Among these 111 positive cases,there were 57 cases (51.4%),21 cases (18.9%),19 cases (7.1%),and 14 cases (12.6%) in the titer of 1:100,1:200,1:400,and 1:800 levels respectively.The positive rate of anti-Pj Msg IgM antibody in HIV infection group was 12.5% (22/176).Among these 22 positive cases,there were 10 cases (45.4%),2 cases (9.1%),4 cases (18.2%),and 6 cases (27.3%) in the titer of 1:100,1:200,1:400,and 1:800 levels respectively.There was no statistical significance in the difference of anti-Pj Msg IgM antibody titer levels compared with non-HIV controls (χ²=3.788,P=0.285).Conclusions Among these non-PCP individuals,the anti-Pj Msg IgG antibody titer levels were mostly between 1:100 and 1:200.The methods of antibody quantitative levels and their clinic significance need further studies.

Key words: Pneumocystis jirovecii, major surface glycoprotein, antibody, quantitative level

CLC Number:

R519

GUO Shuang, LIU Yi, TIAN Xiao-jun, LI Shao-gang, SONG Ying-gai, REN Yi. Quantitative levels of anti-Pneumocystis jirovecii major surface glycoprotein IgG and IgM antibodies in HIV and non-HIV groups[J]. Chinese Journal of Mycology, 2017, 12(6): 342-345.

References

[1] Krajicek BJ,Limper AH,Thomas CF Jr.Advances in the biology,pathogenesis and identification of Pneumocystis pneumonia[J].Curr Opin Pulm Med,2008,14(3):228-234.
[2] Larsen HH,von Linstow ML,Lundgren B,et al.Primary pneumocystis infection in infants hospitalized with acute respiratory tract infection[J].Emerg Infect Dis,2007,13(1):66-72.
[3] Vargas SL,Hughes WT,Santolaya ME,et al.Search for primary infection by Pneumocystis carinii in a cohort of normal,healthy infants[J].Clin Infect Dis,2001,32(6):855-861.
[4] Tanaka M,Sakai R,Koike R,et al.Pneumocystis Jirovecii Pneumonia in Japanese Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors:A Pooled Analysis of 3 Agents[J].J Rheumatol,2015,42(9):1726-1728.
[5] Yamasaki S,Kohno K,Kadowaki M,et al.Prophylaxis against Pneumocystis jirovecii pneumonia in patients with adult T-cell lymphoma /leukemia receiving anti-CC chemokine receptor 4 monoclonal antibody[J].J Infect,2015,71(6):700-702.
[6] Thomas CF Jr,Limper AH.Pneumocystis pneumonia[J].N Engl J Med,2004,350(24):2487-2498.
[7] Thomas CF Jr,Limper AH.Current insights into the biology and pathogenesis of Pneumocystis pneumonia[J].Nat Rev Microbiol,2007,5(4):298-308.
[8] Krajicek BJ,Thomas CF Jr,Limper AH.Pneumocystis pneumonia: current concepts in pathogenesis,diagnosis,and treatment[J].Clin Chest Med,2009,30(2):265-278.
[9] 宋营改,乌姗娜,徐安健,等.耶氏肺孢子菌主要表面糖蛋白合成及人群IgG抗体调查[J].中国病原生物学杂志,2014,9(4):318-321.
[10] Ma L,Chen Z,Huang DW,et al.Genome analysis of three Pneumocystis species reveals adaptation mechanisms to life exclusively in mammalian hosts[J].Nat Commun,2016,7:10740.
[11] Daly K,Koch J,Respaldiza N,et al.Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens[J].Clin Microbiol Infect,2009,15(10):937-942.
[12] Kutty G,England KJ,Kovacs JA.Expression of Pneumocystis jirovecii major surface glycoprotein in Saccharomyces cerevisiae[J].J Infect Dis,2013,208(1):170-179.
[13] Daly KR,Fichtenbaum CJ,Tanaka R,et al.Serologic responses to epitopes of the major surface glycoprotein of Pneumocystis jiroveci differ in human immunodeficiency virus-infected and uninfected persons[J].J Infect Dis,2002,186(5):644-651.
[14] Gingo MR,Lucht L,Daly KR,et al.Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia[J].J Acquir Immune Defic Syndr,2011,57(3):190-196.
[15] Walzer PD,Djawe K,Levin L,et al.Long-Term Serologic Responses to the Pneumocystis jirovecii Major Surface Glycoprotein in HIV-Positive Individuals With and Without P.jirovecii Infection[J].J Infect Dis,2009,199(9):1335-1344.
[16] Daly KR,Koch J,Levin L,et al.Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jirovecii[J].Emerg Infect Dis,2004,10(5):848-854.
[17] Bishop LR,Kovacs JA.Quantitation of anti-Pneumocystis jiroveci antibodies in healthy persons and immunocompromised patients[J].J Infect Dis,2003,187(12):1844-1848.